A Study of Injection HB002.1T in Subjects With Solid Tumor
Status:
Completed
Trial end date:
2020-03-21
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic
profile of HB002.1T, a human immunoglobulin Fc fusion protein containing domain 2 and
flanking sequence of vascular endothelial growth factor (VEGF) receptor-1 in subjects with
solid tumor.